World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
39894
World Ranking
7942
National Ranking
4129

Overview

Ronald Hoffman is affiliated with Mount Sinai Hospital in the United States and has contributed extensively to medical research, particularly in the fields of genetics, hematology, and molecular biology. Their work focuses heavily on myeloproliferative neoplasms, acute myeloid leukemia, and related hematological disorders.

Their main fields of study include:

  • Medicine

Within these domains, Hoffman's research further delves into the following subfields:

  • Genetics
  • Hematology
  • Molecular Biology
  • Rheumatology
  • Physiology

The scientist's research topics highlight specific disease areas such as:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Hemoglobinopathies and Related Disorders
  • Eosinophilic Disorders and Syndromes
  • Kruppel-like factors research
  • Multiple Myeloma Research and Treatments

Ronald Hoffman has published in several prominent venues, including:

  • Blood
  • Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature
  • Clinical Lymphoma Myeloma & Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Leukemia

Notable recent papers include:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data (2022), Blood
  • Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis (2021), Journal of Clinical Oncology
  • Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis (2020), Blood
  • Clinical insights into the origins of thrombosis in myeloproliferative neoplasms (2020), Blood
  • MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis (2023), Journal of Clinical Oncology

Frequent co-authors in their research collaborations include:

  • John Mascarenhas
  • Marina Kremyanskaya
  • Raajit K. Rampal
  • Yelena Ginzburg
  • Srđan Verstovšek

Best Publications

  • Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

    Amelia Bartholomew;Cord Sturgeon;Mandy Siatskas;Karen Ferrer

  • Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates

    Steven M Devine;Carrington Cobbs;Matt Jennings;Amelia Bartholomew

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

    Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka

  • The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.

    H E Broxmeyer;D E Williams;L Lu;S Cooper

  • Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

    Steven M. Devine;Amelia M. Bartholomew;Nadim Mahmud;Mary Nelson

  • A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction.

    Howard A. Pearson;Jeffrey S. Lobel;Samuel A. Kocoshis;J. Lawrence Naiman

  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

    Tiziano Barbui;Ayalew Tefferi;Alessandro M. Vannucchi;Francesco Passamonti

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

    C R Nichols;G Tricot;S D Williams;K van Besien

  • Suppression of Erythroid-Colony Formation by Lymphocytes from Patients with Aplastic Anemia

    Ronald Hoffman;Esmail D. Zanjani;John D. Lutton;Ralph Zalusky

  • Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

    Yogen Saunthararajah;Cheryl A. Hillery;Don Lavelle;Robert Molokie

  • International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

    Ayalew Tefferi;Giovanni Barosi;Ruben A. Mesa;Francisco Cervantes

  • Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

    John Mascarenhas;Ronald Hoffman;Moshe Talpaz;Aaron T. Gerds

  • Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

    Giovanni Barosi;Ruben Mesa;Guido Finazzi;Claire Harrison

  • Role of c-kit ligand in the expansion of human hematopoietic progenitor cells

    John Brandt;Robert A. Briddell;Edward F. Srour;Thomas B. Leemhuis

  • Human CD34(+) stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi.

    Arun K. Sharma;Mary C. Nelson;John E. Brandt;Maija Wessman

  • Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A

    Mohammed Milhem;Nadim Mahmud;Donald Lavelle;Hiroto Araki

  • Somatic mutations and cell identity linked by Genotyping of Transcriptomes

    Anna S. Nam;Kyu-Tae Kim;Ronan Chaligne;Franco Izzo

  • Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

    John Mascarenhas;Ronald Hoffman

Frequent Co-Authors

Mingjiang Xu
Mingjiang Xu National Institutes of Health
Edward F. Srour
Edward F. Srour Indiana University
Giovanni Barosi
Giovanni Barosi University of Pavia
Edward J. Benz
Edward J. Benz Harvard University
George Weber
George Weber Indiana University
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Richard T. Silver
Richard T. Silver Cornell University
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Josef T. Prchal
Josef T. Prchal University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical studies in the USA opens doors to a wide range of online healthcare degrees and flexible career options. If you’re seeking advanced roles in research, teaching, or clinical leadership, consider phd in nursing online programs, which offer a blend of academic rigor and remote accessibility.

Many professionals choose to advance their nursing credentials through flexible, affordable pathways. If you’re a registered nurse, look for rn to bsn cheapest degree options that combine budget-friendly tuition with convenience.

For those with non-nursing backgrounds eager to enter the field quickly, the cheapest direct entry msn programs can lead to an MSN in a streamlined timeframe, allowing you to kick-start your nursing career without a prior BSN.

Additionally, students who want accessible entry points into nursing should research easy nursing programs to get into. These programs can help ease the admission process while providing a solid foundation for a rewarding healthcare career.

Best Scientists Citing Ronald Hoffman

Trending Scientists